Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
IsraelIPO:
03 April 2023Website:
http://www.shl-telemedicine.comNext earnings report:
20 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 20 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
SHLT Latest News
TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO,.
What type of business is SHL Telemedicine?
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
What sector is SHL Telemedicine in?
SHL Telemedicine is in the Healthcare sector
What industry is SHL Telemedicine in?
SHL Telemedicine is in the Health Information Services industry
What country is SHL Telemedicine from?
SHL Telemedicine is headquartered in Israel
When did SHL Telemedicine go public?
SHL Telemedicine initial public offering (IPO) was on 03 April 2023
What is SHL Telemedicine website?
https://www.shl-telemedicine.com
Is SHL Telemedicine in the S&P 500?
No, SHL Telemedicine is not included in the S&P 500 index
Is SHL Telemedicine in the NASDAQ 100?
No, SHL Telemedicine is not included in the NASDAQ 100 index
Is SHL Telemedicine in the Dow Jones?
No, SHL Telemedicine is not included in the Dow Jones index
When does SHL Telemedicine report earnings?
The next expected earnings date for SHL Telemedicine is 20 September 2024